The role of the cytokines IL-27 and IL-35 in cancer

Avner  Friedman; Kang-Ling  Liao; Avner  Friedman; Kang-Ling  Liao

doi:10.3934/mbe.2015.12.1203

Mathematical Biosciences and Engineering

2015, Volume 12, Issue 6: 1203-1217. doi: 10.3934/mbe.2015.12.1203

Previous Article Next Article

The role of the cytokines IL-27 and IL-35 in cancer

Avner Friedman ¹,
Kang-Ling Liao ²

1.
Mathematical Biosciences Institute, The Ohio State University, Columbus, OH 43210
2.
Mathematical Biosciences Institute, The Ohio State University, Columbus, OH

Received: 01 October 2014 Accepted: 29 June 2018 Published: 01 August 2015
MSC : 92C50, 92C37, 92C45, 35Q92, 35Q68.

The cancer-immune interaction is a fast growing field of research in biology, where the goal is to harness the immune system to fight cancer more effectively. In the present paper we review recent work of the interaction between T cells and cancer. CD8$^+$ T cells are activated by IL-27 cytokine and they kill tumor cells. Regulatory T cells produce IL-35 which promotes cancer cells by enhancing angiogenesis, and inhibit CD8$^+$ T cells via TGF-$\beta$ production. Hence injections of IL-27 and anti-IL-35 are both potentially anti-tumor drugs.The models presented here are based on experimental mouse experiments, and their simulations agree with these experiments. The models are used to suggest effective schedules for drug treatment.

Keywords:

Citation: Avner Friedman, Kang-Ling Liao. The role of the cytokines IL-27 and IL-35 in cancer[J]. Mathematical Biosciences and Engineering, 2015, 12(6): 1203-1217. doi: 10.3934/mbe.2015.12.1203

Related Papers:

[1]	K. E. Starkov, Svetlana Bunimovich-Mendrazitsky . Dynamical properties and tumor clearance conditions for a nine-dimensional model of bladder cancer immunotherapy. Mathematical Biosciences and Engineering, 2016, 13(5): 1059-1075. doi: 10.3934/mbe.2016030
[2]	K. Renee Fister, Jennifer Hughes Donnelly . Immunotherapy: An Optimal Control Theory Approach. Mathematical Biosciences and Engineering, 2005, 2(3): 499-510. doi: 10.3934/mbe.2005.2.499
[3]	OPhir Nave, Shlomo Hareli, Miriam Elbaz, Itzhak Hayim Iluz, Svetlana Bunimovich-Mendrazitsky . BCG and IL − 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method—stability analysis. Mathematical Biosciences and Engineering, 2019, 16(5): 5346-5379. doi: 10.3934/mbe.2019267
[4]	Amit Kumar Roy, Priti Kumar Roy, Ellina Grigorieva . Mathematical insights on psoriasis regulation: Role of Th₁ and Th₂ cells. Mathematical Biosciences and Engineering, 2018, 15(3): 717-738. doi: 10.3934/mbe.2018032
[5]	Peter S. Kim, Joseph J. Crivelli, Il-Kyu Choi, Chae-Ok Yun, Joanna R. Wares . Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. Mathematical Biosciences and Engineering, 2015, 12(4): 841-858. doi: 10.3934/mbe.2015.12.841
[6]	Atefeh Afsar, Filipe Martins, Bruno M. P. M. Oliveira, Alberto A. Pinto . A fit of CD4⁺ T cell immune response to an infection by lymphocytic choriomeningitis virus. Mathematical Biosciences and Engineering, 2019, 16(6): 7009-7021. doi: 10.3934/mbe.2019352
[7]	Yuedan Wang, Jinke Huang, Jiaqi Zhang, Fengyun Wang, Xudong Tang . Identifying biomarkers associated with the diagnosis of ulcerative colitis via bioinformatics and machine learning. Mathematical Biosciences and Engineering, 2023, 20(6): 10741-10756. doi: 10.3934/mbe.2023476
[8]	Roman Gumzej . Intelligent logistics systems in E-commerce and transportation. Mathematical Biosciences and Engineering, 2023, 20(2): 2348-2363. doi: 10.3934/mbe.2023110
[9]	Bindu Kumari, Chandrashekhar Sakode, Raghavendran Lakshminarayanan, Prasun K. Roy . Computational systems biology approach for permanent tumor elimination and normal tissue protection using negative biasing: Experimental validation in malignant melanoma as case study. Mathematical Biosciences and Engineering, 2023, 20(5): 9572-9606. doi: 10.3934/mbe.2023420
[10]	Alexander P. Krishchenko, Konstantin E. Starkov . The four-dimensional Kirschner-Panetta type cancer model: How to obtain tumor eradication?. Mathematical Biosciences and Engineering, 2018, 15(5): 1243-1254. doi: 10.3934/mbe.2018057

Abstract

References

[1]	Pharmacological Reviews, 55 (2003), 241-269.
[2]	PLoS ONE, 6 (2011), e18534.
[3]	Principles of Immunopharmacology: 3rd revised and extended edition, 2011.
[4]	The Journal of Experimental Medicine, 178 (1993), 1223-1230.
[5]	Toxicologic Pathology, 27 (1999), 58-63.
[6]	J. Immunol., 186 (2011), 6661-6666.
[7]	Journal of the National Cancer Institute, 89 (1997), 1049-1058.
[8]	Bull. Math. Biol., 74 (2012), 2752-2777.
[9]	Anticancer Res., 24 (2004), 3763-3767.
[10]	Blood, 116 (2010), 3887-3898.
[11]	Nature, 450 (2007), 566-569.
[12]	Immunol. Rev., 226 (2008), 248-262.
[13]	Nature immunology, 13 (2012), 290-299.
[14]	Cytokine Growth Factor Rev., 13 (2002), 155-168.
[15]	J. Immunology, 186 (2011), 83-91.
[16]	Immunity, 21 (2004), 831-842.
[17]	Cancer Res., 69 (2009), 2133-2140.
[18]	Blood, 117 (2011), 323-331.
[19]	Blood, 98 (2001), 2143-2151.
[20]	Nat. Rev. Immunol., 12 (2012), 253-268.
[21]	J Immunol, 160 (1998), 3188-3193.
[22]	J. Immunol, 162 (1999), 1723-1729.
[23]	Cancer Res, 64 (2004), 1152-1156.
[24]	J. Immunol., 183 (2009), 6217-6226.
[25]	Nat Rev Immunol, 5 (2005), 521-531.
[26]	Modern Pathology, 24 (2011), 801-809.
[27]	J Immunol., 178 (2007), 7571-7580.
[28]	Acta Otolaryngol, 127 (2007), 532-539.
[29]	Mol. Cells, 36 (2013), 571-576.
[30]	Carcinogenesis, 34 (2012), 658-666.
[31]	PLoS ONE, 9 (2014), e91844.
[32]	PLoS ONE, 9 (2014), e110126.
[33]	European J. of Immunology, 43 (2013), 468-479.
[34]	J. Immunol., 169 (2002), 2756-2761.
[35]	Biochemical and Biophysical Research Communications, 430 (2013), 364-369.
[36]	J. Investigative Dermatology, 132 (2012), 864-871.
[37]	J. Theor. Biol., 351 (2014), 74-82.
[38]	Cancer Res., 73 (2013), 3007-3018.
[39]	Science (Wash DC), 268 (1995), p1555.
[40]	J. Biomed Biotechnol, 2010 (2010), Article ID 605483, 10 pages.
[41]	Cancer Cell, 20 (2011), 781-796.
[42]	J. Clin Invest., 117 (2007), 50-59.
[43]	BMC Immunol, 14 (2013), p30.
[44]	Hum Gene Ther, 8 (1997), 1303-1311.
[45]	2010.
[46]	International Immunology, 21 (2012), 1105-1111.
[47]	J. Immunol., 182 (2009), 4328-4338.
[48]	J. Immunol., 173 (2004), 7170-7182.
[49]	Am. J. Pathol., 160 (2002), 1787-1798.
[50]	Int. J. Cancer, 124 (2009), 1372-1378.
[51]	Clinical Cancer Research, 13 (2007), 4345-4354.
[52]	Oncoimmunology, 2 (2013), e25409.
[53]	J. Theor. Biol., 303 (2012), 141-151.
[54]	Cancer Res., 72 (2012), 420-429.
[55]	Cancer Res., 72 (2012), 3987-3996.
[56]	Cancer Cell, 8 (2005), 369-380.
[57]	Int Immunol, 14 (2003), 1495-1504.
[58]	Nat. Rev. Immunol., 8 (2008), 523-532.
[59]	Nature immunology, 13 (2012), 722-728.
[60]	J. Experimental and Clinical Cancer Research, 30 (2011), p62.
[61]	J. Immuno., (2013).
[62]	J Immunol, 187 (2011), 266-273.
[63]	Clin. Cancer Res., 11 (2005), 8326-8331.
[64]	Clinical and Developmental immunology, 2010 (2010), Article ID 832454, 9 pages.
[65]	J. Mol Cell Biol., 5 (2013), 207-209.
[66]	2014 Genitourinary Cancer Symposium, 2014.
[67]	Int J Clin Exp Pathol, 6 (2013), 1806-1816.
[68]	J. Immunol., 184 (2010), 2348-2354.
[69]	J. Cell Physiol., 228 (2013), 1127-1136.

This article has been cited by:

1.	Linkun Hu, Cheng Chen, Jun Zhang, Kerong Wu, Xuefeng Zhang, Haiyan Liu, Jianquan Hou, IL-35 Pretreatment Alleviates Lipopolysaccharide-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB Activation, 2017, 40, 0360-3997, 1393, 10.1007/s10753-017-0582-9
2.	Manouchehr Teymouri, Matteo Pirro, Francesca Fallarino, Marco Gargaro, Amirhosein Sahebkar, IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases, 2018, 143, 00207136, 2105, 10.1002/ijc.31382
3.	Xuefen Li, Xia Liu, Weilin Wang, IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases, 2021, 9, 2296-634X, 10.3389/fcell.2021.614847
4.	Arezoo Bassagh, Mehdi Hayatbakhsh Abasi, Tiziana Larussa, Motahareh Ghazizadeh, Maryam Nemati, Ehsan Mirkamandar, Abdollah Jafarzadeh, Diminished circulating concentration of interleukin-35 in Helicobacter pylori -infected patients with peptic ulcer: Its association with FOXP3 gene polymorphism, bacterial virulence factor CagA, and gender of patients, 2018, 23, 10834389, e12501, 10.1111/hel.12501
5.	Lanlan Yang, Xue Shao, Shengnan Jia, Qian Zhang, Zhenjing Jin, Interleukin-35 Dampens CD8+ T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma, 2019, 10, 1664-3224, 10.3389/fimmu.2019.01032
6.	Jing-Jing Zhu, Ning-Ning Shan, Immunomodulatory cytokine interleukin-35 and immune thrombocytopaenia, 2020, 48, 0300-0605, 030006052097647, 10.1177/0300060520976477
7.	Ming-Xi Liu, Qing-Yu Liu, Ye Liu, Zhi-Ming Cheng, Lei Liu, Lei Zhang, Da-Hui Sun, Interleukin-35 suppresses antitumor activity of circulating CD8+ T cells in osteosarcoma patients, 2019, 60, 0300-8207, 367, 10.1080/03008207.2018.1552267
8.	Siqi Liu, Lanlan Yang, Shengnan Jia, Rui Zhao, Zhenjing Jin, Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma, 2021, 100, 15675769, 108161, 10.1016/j.intimp.2021.108161
9.	Ashok Patidar, Sathishkumar Selvaraj, Mohona Chakravarti, Ipsita Guha, Avishek Bhuniya, Saurav Bera, Sukanya Dhar, Kamalika Roy, Rathindranath Baral, Debprasad Chattopadhyay, Chiranjib Pal, Bhaskar Saha, TLR induced IL-27 plays host-protective role against B16BL6 melanoma in C57BL/6 mice, 2022, 154, 10434666, 155871, 10.1016/j.cyto.2022.155871
10.	Marta Smycz‑Kubańska, Sebastian Stępień, Joanna Gola, Celina Kruszniewska‑Rajs, Dominika Wendlocha, Patrycja Królewska‑Daszczyńska, Anna Strzelec, Jarosław Strzelczyk, Wojciech Szanecki, Andrzej Witek, Aleksandra Mielczarek‑Palacz, Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance, 2022, 26, 1791-2997, 10.3892/mmr.2022.12812
11.	Anna K. Rekowska, Karolina Obuchowska, Magdalena Bartosik, Żaneta Kimber-Trojnar, Magdalena Słodzińska, Magdalena Wierzchowska-Opoka, Bożena Leszczyńska-Gorzelak, Biomolecules Involved in Both Metastasis and Placenta Accreta Spectrum—Does the Common Pathophysiological Pathway Exist?, 2023, 15, 2072-6694, 2618, 10.3390/cancers15092618
12.	Lina Ying, Luping Gong, Sicen Meng, Xiudi Wu, Mingcai Li, Yan Li, Circulating interleukin-39 as a potential biomarker for rheumatoid arthritis diagnosis, 2023, 00099120, 110616, 10.1016/j.clinbiochem.2023.110616
13.	Akbar Soleimani Babadi, Arda Kiani, Esmaeil Mortaz, Kimia Taghavi, Adnan Khosravi, Majid Marjani, Sharareh Seifi, Habib Emami, Atefeh Abedini, Serum Interleukin-27 Level in Different Clinical Stages of Lung Cancer, 2019, 7, 1857-9655, 45, 10.3889/oamjms.2019.018
14.	Abeer S. Alnahdi, Muhammad Idrees, Nonlinear dynamics of estrogen receptor-positive breast cancer integrating experimental data: A novel spatial modeling approach, 2023, 20, 1551-0018, 21163, 10.3934/mbe.2023936
15.	Xuan Cai, Ruo‐Yun Gui, Jin Wu, Chen‐Cong Wang, Xiao‐Lu Zhu, Hai‐Xia Fu, Xiao‐Hui Zhang, Decreased Expression of IL‐35 and Its Receptor Contributes to Impaired Megakaryopoiesis in the Pathogenesis of Immune Thrombocytopenia, 2024, 2198-3844, 10.1002/advs.202305798
16.	Nanxi Shi, Xue Xia, Yiming Chen, Yingying Ye, Xin Tang, Zhenhua Li, Bibliometrics analysis of IL-27 as a unique cytokine (2002–2023) and impact on cancer progression, 2024, 2, 2957-8701, 9340033, 10.26599/AGR.2024.9340033
17.	Leila Kiani, Mozhdeh Momtahan, Zahra Shiravani, Abbas Ghaderi, Mohammad Javad Fattahi, Shaghayegh Moradi Alamdarloo, Atefeh Hashemi, Razieh Arman, Seyed Hamdollah Mosavat, Role of serum IL-35 levels in patients with benign and malignant primary ovarian tumors: a case-control study, 2025, 15, 2045-2322, 10.1038/s41598-025-97349-w

Reader Comments

Your name:*

Email:*
© 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)